Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation

Ruth Pettengell; Norbert Schmitz; Christian Gisselbrecht; Graeme Smith; William N Patton; Bernd Metzner; Dolores Caballero; Herve Tilly; Jan A Walewski; Isabelle Bence-Bruckler; Bik To; Christian H Geisler; Rik Schots; Eva Kimby; Christian J Taverna; Tomás Kozák; Peter Dreger; Ruzena Uddin; Carmen Ruiz de Elvira; Anthony H Goldstone

doi:10.1200/JCO.2012.47.1862

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation

Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Graeme Smith, William N Patton, Bernd Metzner, Dolores Caballero, Herve Tilly, Jan A Walewski, Isabelle Bence-Bruckler, Bik To, Christian H Geisler, Rik Schots, Eva Kimby, Christian J Taverna, Tomás Kozák, Peter Dreger, Ruzena Uddin, Carmen Ruiz de Elvira, Anthony H Goldstone

114 Citations (Scopus)

Abstract

The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

Original language	English
Journal	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume	31
Issue number	13
Pages (from-to)	1624-30
Number of pages	7
ISSN	0732-183X
DOIs	https://doi.org/10.1200/JCO.2012.47.1862
Publication status	Published - 1 May 2013

Keywords

Adult
Aged
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Bone Marrow Purging
Combined Modality Therapy
Female
Humans
Lymphoma, Follicular
Male
Middle Aged
Prospective Studies
Recurrence
Salvage Therapy
Stem Cell Transplantation
Transplantation, Autologous

Access to Document

10.1200/JCO.2012.47.1862

Fingerprint

Dive into the research topics of 'Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation'. Together they form a unique fingerprint.

Cite this

Pettengell, R., Schmitz, N., Gisselbrecht, C., Smith, G., Patton, W. N., Metzner, B., Caballero, D., Tilly, H., Walewski, J. A., Bence-Bruckler, I., To, B., Geisler, C. H., Schots, R., Kimby, E., Taverna, C. J., Kozák, T., Dreger, P., Uddin, R., Ruiz de Elvira, C., & Goldstone, A. H. (2013). Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(13), 1624-30. https://doi.org/10.1200/JCO.2012.47.1862

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. / Pettengell, Ruth; Schmitz, Norbert; Gisselbrecht, Christian et al.
In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 31, No. 13, 01.05.2013, p. 1624-30.

Research output: Contribution to journal › Journal article › Research › peer-review

Pettengell, R, Schmitz, N, Gisselbrecht, C, Smith, G, Patton, WN, Metzner, B, Caballero, D, Tilly, H, Walewski, JA, Bence-Bruckler, I, To, B, Geisler, CH, Schots, R, Kimby, E, Taverna, CJ, Kozák, T, Dreger, P, Uddin, R, Ruiz de Elvira, C & Goldstone, AH 2013, 'Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, no. 13, pp. 1624-30. https://doi.org/10.1200/JCO.2012.47.1862

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 May 1;31(13):1624-30. doi: 10.1200/JCO.2012.47.1862

Pettengell, Ruth ; Schmitz, Norbert ; Gisselbrecht, Christian et al. / Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma : a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 ; Vol. 31, No. 13. pp. 1624-30.

@article{c1facca54a764c3ca6a480c86b22299d,

title = "Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation",

abstract = "The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).",

keywords = "Adult, Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Bone Marrow Purging, Combined Modality Therapy, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Prospective Studies, Recurrence, Salvage Therapy, Stem Cell Transplantation, Transplantation, Autologous",

author = "Ruth Pettengell and Norbert Schmitz and Christian Gisselbrecht and Graeme Smith and Patton, \{William N\} and Bernd Metzner and Dolores Caballero and Herve Tilly and Walewski, \{Jan A\} and Isabelle Bence-Bruckler and Bik To and Geisler, \{Christian H\} and Rik Schots and Eva Kimby and Taverna, \{Christian J\} and Tom{\'a}s Koz{\'a}k and Peter Dreger and Ruzena Uddin and \{Ruiz de Elvira\}, Carmen and Goldstone, \{Anthony H\}",

year = "2013",

month = may,

day = "1",

doi = "10.1200/JCO.2012.47.1862",

language = "English",

volume = "31",

pages = "1624--30",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "13",

}

TY - JOUR

T1 - Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma

T2 - a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation

AU - Pettengell, Ruth

AU - Schmitz, Norbert

AU - Gisselbrecht, Christian

AU - Smith, Graeme

AU - Patton, William N

AU - Metzner, Bernd

AU - Caballero, Dolores

AU - Tilly, Herve

AU - Walewski, Jan A

AU - Bence-Bruckler, Isabelle

AU - To, Bik

AU - Geisler, Christian H

AU - Schots, Rik

AU - Kimby, Eva

AU - Taverna, Christian J

AU - Kozák, Tomás

AU - Dreger, Peter

AU - Uddin, Ruzena

AU - Ruiz de Elvira, Carmen

AU - Goldstone, Anthony H

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

AB - The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Agents

KW - Bone Marrow Purging

KW - Combined Modality Therapy

KW - Female

KW - Humans

KW - Lymphoma, Follicular

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Recurrence

KW - Salvage Therapy

KW - Stem Cell Transplantation

KW - Transplantation, Autologous

UR - https://www.scopus.com/pages/publications/84883265147

U2 - 10.1200/JCO.2012.47.1862

DO - 10.1200/JCO.2012.47.1862

M3 - Journal article

C2 - 23547078

SN - 0732-183X

VL - 31

SP - 1624

EP - 1630

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

IS - 13

ER -

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this